1.Munoz, N, et al. International Agency for Research on Cancer Multicenter cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527.
2.Remmink, AJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. International Journal of Cancer 1995; 61: 306–311.
3.Li, N, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. Journal of Infectious Diseases 2011; 204: 217–223.
4.Hobbs, C, et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clinical Otolaryngology 2006; 31: 259–266.
5.Erickson, BK, et al. Human papillomavirus: what every provider should know. American Journal of Obstetrics and Gynecology 2013; 208: 169–175.
6.Hernandez-Giron, C, et al. High-risk human papillomavirus detection and related risk factors among pregnant and non-pregnant women in Mexico. Sexually Transmitted Diseases 2005; 32: 613–618.
7.Hariri, S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. Journal of Infectious Diseases 2011; 204: 566–573.
8.Vaccarella, S, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. International Journal of Epidemiology 2008; 37: 536–546.
9.Weinberg, ED. Pregnancy-associated depression of cell-mediated immunity. Review of Infectious Diseases 1984; 6: 814–831.
10.Sillman, F, Sedlis, A. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstetrics and Gynecology Clinics of North America 1987; 14: 537.
11.Gloss, B, et al. The upstream regulatory region of the human papillomavirus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBO Journal 1987; 6: 3735.
12.Merckx, M, et al. Transmission of carcinogenic human papillomavirus types from mother to child: a meta-analysis of published studies. European Journal of Cancer Prevention 2012.
13.Sillman, F, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. American Journal of Obstetrics and Gynecology 1984; 150: 300–308.
14.Schneider, A, Hotz, M, Gissmann, L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. International Journal of Cancer 1987; 40: 198–201.
15.Czegledy, J, Gergely, L, Endrodi, I. Detection of human papillomavirus deoxyribonucleic acid by filter in situ hybridization during pregnancy. Journal of Medical Virology 1989; 28: 250–254.
16.Chang-Claude, J, et al. Longitudinal study of the effects of pregnancy and other factors on detection of HPV. Gynecologic Oncology 1996; 60: 355–362.
17.Fife, KH, et al. Cancer-associated human papillomavirus types are selectively increased in the cervix of women in the first trimester of pregnancy. American Journal of Obstetrics and Gynecology 1996; 174: 1487–1493.
18.Aydin, Y, et al. Prevalence of human papilloma virus infection in pregnant Turkish women compared with non-pregnant women. European Journal of Gynaecological Oncology 2010; 31: 72–74.
19.Soares, VR, et al. Human papillomavirus DNA in unselected pregnant and non-pregnant women. International Journal of STD & AIDS 1990; 1: 276–278.
20.Smith, E, et al. The association between pregnancy and human papilloma virus prevalence. Cancer Detection and Prevention 1991; 15: 397.
21.De, Roda Husman AM, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. Journal of Medical Virology 1995; 46: 97–102.
22.Morrison, EAB, et al. Pregnancy and cervical infection with human papillomaviruses. International Journal of Gynecology and Obstetrics 1996; 54: 125–130.
23.Tenti, P, et al. Latent human papillomavirus infection in pregnant women at term: a case-control study. Journal of Infectious Diseases 1997; 176: 277–280.
24.Chan, PKS, et al. Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and non-pregnant controls. Journal of Medical Virology 2002; 67: 583–588.
25.Zlatkov, V, et al. A study on the Cervical epithelium of women in early pregnancy – histological findings and human papillomavirus characterization. Journal of the Balkan Union of Oncology 2003; 8: 269–272.
26.Schmeink, CE, et al. Human papillomavirus detection in pregnant women: a prospective matched cohort study. Journal of Women's Health (2002) 2012; 21: 1295–1301.
27.Duckitt, K, Harrington, D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. British Medical Journal 2005; 330: 565.
28.Wei, S-Q, et al. Maternal vitamin D status and adverse pregnancy outcomes: a systematic review and meta-analysis. Journal of Maternal-Fetal & Neonatal Medicine 2013; 26: 889–899.
29.Hong, Y, et al. Survey of human papillomavirus types and their vertical transmission in pregnant women. BMC Infectious Diseases 2013; 13: 109.
30.Yamasaki, K, et al. Epidemiology of human papillomavirus genotypes in pregnant Japanese women. Journal of Human Genetics 2011; 56: 313–315.
31.Takakuwa, K, et al. Studies on the prevalence of human papillomavirus in pregnant women in Japan. Journal of Perinatal Medicine 2006; 34: 77–79.
32.Zhou, X, Huang, J. The relativity analysis of pregnancy and the susceptibility of high risk human papillomavirus infection. Journal of Chinese Eugenics and Genetics 2011; 19: 60–61.
33.Zhou, B, et al. The Prospective study of the HPV infection subtypes in pregnancy and vertical transmission. Progress in Obstetrics and Gynecology 2012; 21: 208–210.
34.Yao, H, Li, J. High-risk human papillomavirus infection analysis for pregnancy and post-partum women. Chinese Medicine 2013; 10: 28–29.
35.Wang, Z, et al. The comparison of the prevalence rate of HPV infection in pregnant and non-pregnant women. Progress in Obstetrics and Gynecology 2008; 17: 423–425.
36.Wang, D, et al. The prevalence of high risk HPV infection in pregnancy. Journal of Preventive Medicine 2010; 22: 564–565.
37.Peng, P, et al. Detection of the asymptomatic Infection by human papillomavirus in Pregnant Women and Neonates. Journal of Chinese Obstetrics and Gynecology 2000; 35: 523–526.
38.Louvanto, K, et al. Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish Family HPV Study. Journal of Infectious Diseases 2010; 202: 436–444.
39.Domža, G, et al. Human papillomavirus infection in pregnant women. Archives of Gynecology and Obstetrics 2011; 284: 1105–1112.
40.Smith, E, et al. HPV prevalence and concordance in the cervix and oral cavity of pregnant women. Infectious Diseases in Obstetrics and Gynecology 2004; 12: 45–56.
41.Peng, TC, et al. Prevalence of human papillomavirus infections in term pregnancy. American Journal of Perinatology 2008; 7: 189–192.
42.Worda, C, et al. Prevalence of cervical and intrauterine human papillomavirus infected in the third trimester in asymptomatic women. Journal of the Society for Gynecologic Investigation 2005; 12: 440–444.
43.De, Sanjosé S, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007; 7: 453–459.
44.Clifford, G, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991–998.
45.Bruni, L, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases 2010; 202: 1789–1799.
46.Ye, J, et al. Prevalence and risk profile of Cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virology Journal 2010; 7: 66.
47.Hørding, U, et al. Prevalence of human papillomavirus types 11, 16 and 18 in cervical swabs. A study of 1362 pregnant women. European Journal of Obstetrics & Gynecology and Reproductive Biology 1990; 35: 191–198.
48.Kemp, EA, et al. Human papillomavirus prevalence in pregnancy. Obstetrics & Gynecology 1992; 79: 649–656.
49.Sarkola, ME, et al. Effect of second pregnancy on maternal carriage and outcome of high-risk human papillomavirus (HPV). Experience from the prospective Finnish family HPV study. Gynecologic and Obstetric Investigation 2009; 67: 208–216.
50.Yamasaki, K, et al. Epidemiology of human papillomavirus genotypes in pregnant Japanese women. Journal of Human Genetics 2011; 56: 313–315.
51.Takuwa, K, et al. Studies on the prevalence of human papillomavirus in pregnant women in Japan. Journal of Perinatal Medicine 2006; 34: 77–79.
52.Snijders, PJ, van den Brule, AJ, Meijer, CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. Journal of Pathology 2003; 201: 1–6.
53.Gravitt, PE, et al. New technologies in cervical cancer screening. Vaccine 2008; 26 (Suppl. 10): K42–K52.
54.Kleter, B, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. Journal of Clinical Microbiology 1999; 37: 2508–2517.
55.Qu, W, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. Journal of Clinical Microbiology 1997; 35: 1304–1310.
56.Da, Silva, et al. Increased frequency of bacterial vaginosis and Chlamydia trachomatis in pregnant women with human papillomavirus infection. Gynecologic and Obstetric Investigation 2004; 58: 189–193.
57.Wang, F, et al. Clinical significance of cervical cytological examination in gestation. Journal of Capital University of Medical Sciences 2005; 26: 604–606.